CY1122572T1 - Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren - Google Patents

Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren

Info

Publication number
CY1122572T1
CY1122572T1 CY20191101354T CY191101354T CY1122572T1 CY 1122572 T1 CY1122572 T1 CY 1122572T1 CY 20191101354 T CY20191101354 T CY 20191101354T CY 191101354 T CY191101354 T CY 191101354T CY 1122572 T1 CY1122572 T1 CY 1122572T1
Authority
CY
Cyprus
Prior art keywords
sjögren
trifluoroethyl
syndrome
treatment
specific
Prior art date
Application number
CY20191101354T
Other languages
English (en)
Inventor
Rodger Anthony Allen
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CY1122572T1 publication Critical patent/CY1122572T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η Ν-{(R)-1-[8-χλωρo-2-(1-oξυπυριδιv-3-υλo)-κιvoλιv-3-υλo]-2,2,2-τριφθoρoαιθυλo}-πυριδο[3,2-d]πυριμιδιν-4-υλαμίνη είναι αποτελεσματική στη θεραπεία ή/και την πρόληψη του συνδρόμου Sjögren.
CY20191101354T 2015-04-21 2019-12-23 Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren CY1122572T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (1)

Publication Number Publication Date
CY1122572T1 true CY1122572T1 (el) 2021-01-27

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101354T CY1122572T1 (el) 2015-04-21 2019-12-23 Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren

Country Status (27)

Country Link
US (1) US10493074B2 (el)
EP (1) EP3285772B1 (el)
JP (1) JP6721606B2 (el)
KR (1) KR102627370B1 (el)
CN (1) CN107530344B (el)
AR (1) AR105552A1 (el)
AU (1) AU2016251236B2 (el)
BR (1) BR112017020591B8 (el)
CA (1) CA2981631C (el)
CL (1) CL2017002669A1 (el)
CO (1) CO2017010573A2 (el)
CY (1) CY1122572T1 (el)
DK (1) DK3285772T3 (el)
EA (1) EA032432B1 (el)
ES (1) ES2763335T3 (el)
GB (1) GB201506786D0 (el)
HR (1) HRP20192273T1 (el)
HU (1) HUE047162T2 (el)
IL (1) IL254766B (el)
LT (1) LT3285772T (el)
MX (1) MX2017013148A (el)
MY (1) MY192972A (el)
PL (1) PL3285772T3 (el)
PT (1) PT3285772T (el)
SG (1) SG11201707789YA (el)
SI (1) SI3285772T1 (el)
WO (1) WO2016170014A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605792T3 (es) * 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
UA98955C2 (ru) * 2007-03-23 2012-07-10 Амген Инк. Гетероциклические соединения и их применение
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
NZ714710A (en) * 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
JP6721606B2 (ja) 2020-07-15
BR112017020591B8 (pt) 2023-05-16
BR112017020591A2 (pt) 2018-07-03
AR105552A1 (es) 2017-10-18
HUE047162T2 (hu) 2020-04-28
EA032432B1 (ru) 2019-05-31
EP3285772A1 (en) 2018-02-28
IL254766A0 (en) 2017-12-31
CN107530344B (zh) 2020-03-17
PL3285772T3 (pl) 2020-05-18
CO2017010573A2 (es) 2018-03-09
CL2017002669A1 (es) 2018-05-11
CA2981631A1 (en) 2016-10-27
LT3285772T (lt) 2020-01-10
KR20170140245A (ko) 2017-12-20
US20180092921A1 (en) 2018-04-05
WO2016170014A1 (en) 2016-10-27
DK3285772T3 (da) 2020-01-13
BR112017020591B1 (pt) 2023-02-07
AU2016251236B2 (en) 2018-06-14
CA2981631C (en) 2023-02-21
EP3285772B1 (en) 2019-10-02
HRP20192273T1 (hr) 2020-03-06
EA201792318A1 (ru) 2018-05-31
CN107530344A (zh) 2018-01-02
SG11201707789YA (en) 2017-11-29
ES2763335T3 (es) 2020-05-28
IL254766B (en) 2020-05-31
KR102627370B1 (ko) 2024-01-18
GB201506786D0 (en) 2015-06-03
MY192972A (en) 2022-09-20
AU2016251236A1 (en) 2017-11-09
SI3285772T1 (sl) 2020-02-28
JP2018513862A (ja) 2018-05-31
MX2017013148A (es) 2018-02-21
US10493074B2 (en) 2019-12-03
PT3285772T (pt) 2020-01-14

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CY1126052T1 (el) 1η-πυρρολο[2,3-c]πυριδιν-7(6η)-ονες και πυραζολο[3,4-c]πυριδιν-7(6η)- ονες ως αναστολεις των bet πρωτεϊνων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
PH12018501589A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
PH12017501780A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
CY1121997T1 (el) Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου
EA201992546A1 (ru) Средства на основе антител к cd33
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2018013559A2 (es) Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds)
LT3759083T (lt) 2,4-diaminochinazolino dariniai ir jų naudojimas virusinės infekcijos, vėžio ir alergijų gydymui
EP3615056A4 (en) METHODS AND COMPOSITIONS FOR THE SCREENING AND TREATMENT OF CANCER
EA201792123A1 (ru) Лечение боли
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
UY33153A (es) Formulación tópica oftálmica de péptidos
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
IL284124A (en) History of quinoline for use in the treatment or prevention of cancer
CY1122572T1 (el) Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren
AU2017394032A8 (en) Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
IT201700109607A1 (it) Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma.
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
CL2018001871A1 (es) Uso de inhibidores de la actividad o función de pi3k para el tratamiento del síndrome de sjögren primario
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі